Related Experiment Video
Updated: Jul 4, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Letter to the Editor: Physical functioning as a neglected determinant of antiviral adherence in chronic hepatitis B
Xiao-Feng Huang1, Jing-Qi Zeng2
1The Third Clinical Medical College, Xinjiang Medical University, Urumqi 830017, Xinjiang Uygur Autonomous Region, China.
Abstract:
As global strategies shift toward expanding treatment eligibility for chronic hepatitis B, ensuring long-term adherence is critical. Block et al recently published a study in World Journal of Virology, challenging the conventional focus on economic barriers and revealing that compromised physical functioning is a significantly more potent predictor of non-adherence than financial affordability. This finding exposes a profound "clinical discordance": Patients may achieve viral suppression yet suffer from residual fatigue and functional impairment, potentially driven by immune exhaustion or metabolic comorbidities. We argue that this symptom burden serves as a functional blockade to daily persistence. Therefore, clinical care must evolve from "adherence policing" to active symptom management. Integrating patient-reported outcomes and addressing physical deficits are essential strategies to safeguard the efficacy of antiviral regimens in the elimination era.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inhibitors of Viral Protein Synthesis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
